search button

The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions

  • Authors:
    • Łukasz Bułdak
    • Grzegorz Machnik
    • Estera Skudrzyk
    • Aleksandra Bołdys
    • Bogusław Okopień

  • View Affiliations

  • Published online on: February 6, 2019     https://doi.org/10.3892/etm.2019.7245
  • Pages: 2861-2869
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

GLP‑1 agonists such as exenatide and liraglutide are novel drugs for the treatment of diabetes and obesity. While improvements in glycemic control can rely on an incretin effect, the mechanisms behind the loss of weight following therapy have yet to be completely elucidated, and seem to be associated with alterations in eating habits, resulting from changes in cytokines e.g. interleukin 1β (IL‑1β) and oxidative signaling in the central nervous system (CNS). Increased levels of IL‑1β and reactive oxygen species have been demonstrated to exert anorexigenic properties, and astrocytes appear to actively participate in maintaining the integrity of the CNS, which includes the paracrine secretion of inflammatory cytokines and involvement in the redox status. Therefore, the present study decided to explore the influence of exenatide [a glucagon‑like peptide 1 (GLP‑1 agonist)] on inflammatory and oxidative stress markers in cultured human astrocytes as a potential target for weight reduction therapies. In an experimental setting, normal human astrocytes were subjected to various glycemic conditions, including 40 mg/dl‑hypoglycemic, 100 mg/dl‑normoglycemic and 400 mg/dl‑hyperglycemic, and exenatide, which is a GLP‑1 agonist. The involvement of intracellular signaling by a protein kinase A (PKA) in the action of exenatide was estimated using a specific PKA inhibitor‑PKI (14‑22). The expression levels of IL‑1β, nuclear factor kappa κB (NFκB), glial‑fibrillary acidic protein (GFAP), p22 NADPH oxidase, glutathione peroxidase, catalase, superoxide dismutase 1, and reactive oxidative species were measured. The present study demonstrated that varying glucose concentrations in the culture media did not affect the protein expression or the level of reactive oxygen species. Conversely, exenatide led to an increase in IL‑1β in normoglycemic culture conditions, which was accompanied by the increased expression of p22, glutathione peroxidase and the reduced expression of GFAP. Changes in the expression of IL‑1β and p22 were dependent on the activation of PKA. The present study concluded that exenatide predominantly affected astrocytes in normoglycemic conditions, and hypothesize that this impact demonstrated one of novel mechanisms associated with astrocyte signaling that may contribute to weight loss.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 17 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Bułdak Ł, Machnik G, Skudrzyk E, Bołdys A and Okopień B: The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Exp Ther Med 17: 2861-2869, 2019
APA
Bułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., & Okopień, B. (2019). The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions. Experimental and Therapeutic Medicine, 17, 2861-2869. https://doi.org/10.3892/etm.2019.7245
MLA
Bułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., Okopień, B."The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions". Experimental and Therapeutic Medicine 17.4 (2019): 2861-2869.
Chicago
Bułdak, Ł., Machnik, G., Skudrzyk, E., Bołdys, A., Okopień, B."The impact of exenatide (a GLP‑1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemic conditions". Experimental and Therapeutic Medicine 17, no. 4 (2019): 2861-2869. https://doi.org/10.3892/etm.2019.7245